BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007; 13(44): 5867-5876 [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867]
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5867.htm
Number Citing Articles
1
Mahnoor Naseer Gondal, Rida Nasir Butt, Osama Shiraz Shah, Muhammad Umer Sultan, Ghulam Mustafa, Zainab Nasir, Risham Hussain, Huma Khawar, Romena Qazi, Muhammad Tariq, Amir Faisal, Safee Ullah Chaudhary. A Personalized Therapeutics Approach Using an In Silico Drosophila Patient Model Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal CancerFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.692592
2
Ricardo Lima Barros Costa. Review Article: Targeted Therapy: Comprehensive ReviewAmerican Journal of Hospice and Palliative Medicine® 2009; 26(2): 137 doi: 10.1177/1049909108330026
3
Yan Ding, Xiaobing Huang, Taiping Liu, Yong Fu, Zhangping Tan, Hong Zheng, Taoli Zhou, Jigang Dai, Wenyue Xu. The Plasmodium Circumsporozoite Protein, a Novel NF-κB Inhibitor, Suppresses the Growth of SW480Pathology & Oncology Research 2012; 18(4): 895 doi: 10.1007/s12253-012-9519-7
4
Shayan Khozooei, Soundaram Veerappan, Irina Bonzheim, Stephan Singer, Cihan Gani, Mahmoud Toulany. Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaksRadiotherapy and Oncology 2023; 188: 109867 doi: 10.1016/j.radonc.2023.109867
5
Fatemeh Afra, Soha Mohammadi, Amir Salehi Farid, Sina Moghaddam, Elahe Meftah, Nima Taghizadeh Mortezaei, Mobina Fathi. Interdisciplinary Cancer Research 2024;  doi: 10.1007/16833_2024_398
6
Martin Benesch, Christian Urban. Bevacizumab for Refractory Solid Tumors in Pediatric PatientsPediatric Health 2008; 2(2): 147 doi: 10.2217/17455111.2.2.147
7
John W. Tumeh, Pareen J. Shenoy, Susan G. Moore, John Kauh, Christopher Flowers. A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal CancerAmerican Journal of Clinical Oncology 2009; 32(1): 49 doi: 10.1097/COC.0b013e31817c6a4d
8
Punnida Nonsuwan, Nattarika Niwetbowornchai, Kanyanut Insawang, Natsuda Kunwong, Kornrawee Srichan, Chatchawan Srisawat, Paweena Dana, Nattika Saengkrit, Kytai T. Nguyen, Primana Punnakitikashem. Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatmentRoyal Society Open Science 2025; 12(4) doi: 10.1098/rsos.241817
9
Asiya Batool, Waseem Rashid, Kaneez Fatima, Sameer Ullah Khan. Drug Resistance in Cancer: Mechanisms and Strategies2024; : 31 doi: 10.1007/978-981-97-1666-1_2
10
Arundhati Jana, Nancy L. Krett, Grace Guzman, Ahmer Khalid, Ozkan Ozden, Jonas J. Staudacher, Jessica Bauer, Seung Hyun Baik, Timothy Carroll, Cemal Yazici, Barbara Jung. NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathwayOncotarget 2017; 8(23): 37377 doi: 10.18632/oncotarget.16343
11
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich. Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal CancerThe Journal of Molecular Diagnostics 2009; 11(5): 381 doi: 10.2353/jmoldx.2009.090003
12
Jesús García-Foncillas, Eduardo Díaz-Rubio. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcomeClinical and Translational Oncology 2010; 12(8): 533 doi: 10.1007/s12094-010-0551-3
13
Smala Shrestha, Amit Shrestha, Jeonghwan Kim, Raj Kumar Thapa, Jong Oh Kim. Recent advances in albumin nanoparticle-based cancer therapiesJournal of Pharmaceutical Investigation 2025; 55(1): 1 doi: 10.1007/s40005-024-00687-6
14
Daniel J. Freeman. Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal CancerClinical Medicine. Therapeutics 2009; 1 doi: 10.4137/CMT.S2039
15
Arundhati Jana, Archita Das, Nancy L. Krett, Grace Guzman, Alexandra Thomas, Georgina Mancinelli, Jessica Bauer, Masuko Ushio-Fukai, Tohru Fukai, Barbara Jung, Salvatore V. Pizzo. Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancerPLOS ONE 2020; 15(1): e0227916 doi: 10.1371/journal.pone.0227916
16
Jeffrey S. Ross, Jorge Torres-Mora, Nikhil Wagle, Timothy A. Jennings, David M. Jones. Biomarker-Based Prediction of Response to Therapy for Colorectal CancerAmerican Journal of Clinical Pathology 2010; 134(3): 478 doi: 10.1309/AJCP2Y8KTDPOAORH
17
John L. Marshall. Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?Journal of Oncology 2009; 2009: 1 doi: 10.1155/2009/937305
18
Jeffrey S Ross. Biomarker-Based Selection of Therapy For Colorectal CancerBiomarkers in Medicine 2011; 5(3): 319 doi: 10.2217/bmm.11.38
19
Alicia Algeciras-Schimnich, Dennis J. O'Kane, Christine L.H. Snozek. Pharmacogenomics of Tamoxifen and Irinotecan TherapiesClinics in Laboratory Medicine 2008; 28(4): 553 doi: 10.1016/j.cll.2008.05.004
20
Ji-Kun Li, Liang Yu, Yun Shen, Li-Sheng Zhou, Yi-Cheng Wang, Jian-Hai Zhang. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells <italic>in vitro</italic>World Journal of Gastroenterology 2008; 14(15): 2308-2313 doi: 10.3748/wjg.14.2308
21
Kei Sakamoto, Shin Maeda, Yohko Hikiba, Hayato Nakagawa, Yoku Hayakawa, Wataru Shibata, Ayako Yanai, Keiji Ogura, Masao Omata. Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor GrowthClinical Cancer Research 2009; 15(7): 2248 doi: 10.1158/1078-0432.CCR-08-1383
22
Béla Pikó. Panitumumab alkalmazása az áttétes vastag- és végbélrákos betegek kezelésébenMagyar Onkológia 2009; 53(2): 135 doi: 10.1556/MOnkol.53.2009.2.5
23
Kei Sakamoto, Shin Maeda. Targeting NF-κB for colorectal cancerExpert Opinion on Therapeutic Targets 2010; 14(6): 593 doi: 10.1517/14728221003769903
24
XUEYING LU, HAIBO WEI, XIAOJIN ZHANG, WENXIN ZHENG, CHENG CHANG, JINYU GU. Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosisOncology Letters 2011; 2(4): 643 doi: 10.3892/ol.2011.299